05 July 2016
The likely relocation of the European Medicines Agency (EMA) from London threatens to disrupt the approval of new drugs and is a medium and long-term worry for top Spanish drugmaker Almirall, its chief executive said on Monday.
The EMA, Europe's equivalent the U.S. Food and Drug Administration, approves medicines for all European Union countries from its headquarters in London's Canary Wharf financial district.
After Britain's vote on June 23 to leave the European Union, it is widely expected to transfer to another city within the EU.
"When they invoke Article 50, EMA will probably leave Britain and this will produce a very large disruption ... it's worrying that the approval process of new pharmaceuticals could be hit by this," Eduardo Sanchiz said.
Article 50 is the EU treaty clause that would trigger two years of negotiations on the terms of Britain's exit from the bloc.
Almirall, one of Spain's top drugmakers, operates mostly in the United States and Europe, with Britain its fifth most important market. As a result, any impact from the devaluation of the pound would be limited, Sanchiz said.
Separately, Sanchiz said Almirall could be interested in acquiring assets of the Canadian drugs company Valeant, although the sales process was still very preliminary.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024